Posted by Michael Wonder on 06 Dec 2023
Neurocrine Biosciences receives breakthrough therapy designation from US FDA for crinecerfont in congenital adrenal hyperplasia
5 December 2023 - Crinecerfont new drug application submission planned in 2024.
Neurocrine Biosciences today announced it received breakthrough therapy designation from the US FDA for crinecerfont in congenital adrenal hyperplasia.
